Thrombin is the key serine proteinase of the coagulation cascade and, therefore, a suitable target for inhibition of blood coagulation. An extract of Amanita virosa considerably inhibited thrombin (48%), but showed no inhibitory activity on trypsin. On the basis of inhibition selectivity between thrombin and trypsin and potency of thrombin inhibition, A. virosa constitutes a good starting material for the isolation of further compounds that are active against thrombin. Bioassay oriented fractionation of the extract of A. virosa led to the isolation of a complex mixture of triglycerides (TGs), monoacylglycerols (MAGs), free fatty acids (FAs) and ergosterol. The structures of the isolated lipids metabolites were determined on the basis of chemical and spectroscopic evidences.
Amanita are the main lethal toadstools among the 1000 poisonous mushrooms known in the world. Almost all fatal human fungus poisonings are caused by one of the Amanita species, Amanita phalloides ('death cap'), A. verna ('white death cap') and A. virosa ('destroying angel') [1] .
A. virosa (Phylum Eumycophyta, Class Basidiomycetes, Order Agaricales, Family Amanitaceae) is a mushroom that is commonly found in aspen-birch, coniferous and hard-wood forests. It is less common than its fellow Amanitas [2] [3] [4] . Intensive research on the toxins of A. virosa led to the isolation and identification of toxic peptides, named virotoxins, since they are found exclusively in A. virosa. Virotoxins are related to phallotoxins in chemical structure and are similar to them in toxicity and biological action [5] . A. virosa also contains two major amatoxins (-amanitin and -amanitin) and two cyclopeptides belonging to the phallotoxin family (phalloidin and phallacidin) [5, 6] . Another toxin found exclusively in A. virosa is amaninamide, closely related to the amatoxins. It differs from -amanitin in that it lacks the 6'-hydroxyl group of the tryptophan unit [7] .
Thrombin is a multifunctional serine protease that plays a primary role in the physiological and pathogenic pathway of thrombosis as a consequence of fibrinogen cleavage to fibrin and protease-activated receptor 1 (PAR-1 or thrombin receptor) activation. Therefore, it represents a suitable and validated target for inhibition of blood coagulation [8] . In a preliminary study, 95 selected mushroom species were screened in order to find novel specific non-peptidic thrombin inhibitors [9] . The extract of A. virosa considerably inhibited thrombin (48% at a concentration of 120 µg/mL).
As part of our continuing interest in bioactive substances from Basidio-mycetes, we previously examined Stereum hirsutum and Gloeophyllum odoratum for new orally active, safe, selective and potent thrombin inhibitors, especially with new molecular scaffolds [10, 11] .
In this paper, we report the isolation and biological investigation of active principles from A. virosa on the basis of thrombin inhibitory potency. Bioassay oriented fractionation of the extract of A. virosa led to the isolation of active compounds. On the basis of spectroscopic data, chemical reactions and GC-MS analysis, complex mixtures of triglycerides (TGs) (1), monoacylglycerols (MAGs) (2), free fatty acids (FAs) (3) and ergosterol (4) have been isolated and identified as active principles.
Purification of the dry extract of A. virosa by column chromatography gave seven fractions (1-7) that were tested for inhibitory activity on thrombin. Fractions 3 and 5 were further purified by column chromatography to give 3A, 3B, 5A and 5B, respectively. Three fractions (1, 3 and 5) were found to significantly inhibit thrombin at a concentration of 120 µg/mL; fraction 1 (27%), fraction 3 (35%) and fraction 5 (27%) ( Table 1) . Further purification by either column chromatography or semipreparative TLC yielded the complex mixtures (1-3) and compound 4 ( Figure 1 followed by methylation of the obtained acids, upon GC-MS analysis also confirmed the presence of palmitic (18.6%), oleic (71.0%) and linoleic (10%) acids [12] . The mixture 1 showed an inhibitory activity of 27% on thrombin at the concentration of 25 µg/mL ( Table 1) . *Each dry fungal fraction was dissolved in DMSO and then added to the reaction mixture to a final concentration of 120 µg/mL. The thrombin activity was defined as the increase of absorbance per minute. For each fraction, the thrombin activity in the reaction mixture with fungal fraction was subtracted from the thrombin activity in the reaction mixture without fungal fraction (positive control). The difference was then expressed as a percentage of the thrombin activity of the positive control and defined as the inhibitory activity on thrombin. The inhibitory activity of argatroban (0.1 µg/mL) on thrombin was 53%. methylation of the obtained acids, upon GC-MS analysis also confirmed the presence of palmitic (25.1%), oleic (60.0%) and linoleic (9.0%) acids [12] . The mixture 2 showed an inhibitory activity of 27% on thrombin at a concentration of 25 µg/mL (Table  1) .
Upon fractionation of fraction 3 with n-hexane/Et 2 O (1:1, v:v), two fractions, 3A and 3B, were obtained. From fraction 3A, the complex mixture 3 was obtained as pale yellow oil. Molecular ion peaks at m/z 279 [M + Na] + , 305 [M + Na] + and 303 [M + Na] + , along with 1 H-and 13 C-NMR spectral data showed molecular formulas of C 16 H 32 O 2 , C 18 H 34 O 2 and C 18 H 32 O 2 , respectively. The presence of strong absorption bands at 3420 and 1720 cm -1 , along with the signal at  C 180.14, suggested the presence of one carboxylic carbonyl in 3. The absence of the typical pattern relative to a glycerol moiety in the 1 H NMR spectrum of 3, but the presence of signals typical of long chains strongly indicated the presence of free fatty acids. Saponification of 3, followed by methylation of the obtained acids, upon GC-MS analysis also confirmed the presence of palmitic (15.5%), oleic (72.0%) and linoleic (12.6%) acids. The mixture of free fatty acids 3 shows an inhibitory activity of 33% on thrombin at a concentration of 25 µg/mL (Table 1) .
From fraction 3B compound 4 was obtained as white needles, which exhibited a positive Liebermann-Burchard reaction. The compound was identified as ergosterol from EI-MS, FT-IR, 1 H and 13 C NMR data. Ergosterol is recognized as a major sterol of fungi and yeasts [13] . Compound 4 showed an inhibitory activity of 18% on thrombin at a concentration of 25 µg/mL (Table 1) . At the concentrations employed (up to 10%), DMSO did not interfere with inhibitory activity measurements.
On the basis of inhibitory potency on thrombin (inhibitory activity 48% at concentration of 25 µg/mL), we have shown that A. virosa Lipid metabolites from Amanita virosa Natural Product Communications Vol. 7 (11) 2012 1497 constitutes a good starting material for isolation and structure elucidation of further compounds that are active against thrombin. A bioassay oriented fractionation of the extract of A. virosa has led to the isolation of lipid mixtures. Our findings suggest that lipid metabolites 1-3 are responsible for the inhibitory activity of the extract on thrombin. GC-MS analysis of the methyl esters indicated the presence of only three kinds of esters among which oleic acid predominated.
Experimental

NMR-spectroscopy:
Nuclear magnetic resonance spectra were recorded with Varian Unity 400 and Varian Gemini 200 MHz spectrometers. 13 C NMR: 100.4 MHz, Unity 400 spectrometer. NMR spectra were obtained using CDCl 3 as solvent; chemical shifts are expressed as  units (ppm) relative to tetramethylsilane (TMS) as internal standard.
Electrospray analysis: API Perkin Elmer (voltage + 5600 with orifice 90 and/or 120). Silica gel CC: Kieselgel 60 (230-400 mesh, 60Å Merck). FT-IR: Jasco IR-700 infrared spectrophotometer. All solvents were distilled before use. TLC: Kieselgel 60 F 254 (20 x 20 cm; 0.2 mm, Merck).
The fatty acid compositions of 1-3 were determined, as methyl esters, using the Association of Official Analytical Chemists (AOAC) methylation procedure and analyzed by GC-MS [12] . A Carlo Erba GC 8000 instrument was coupled directly to a MD 800 mass spectrometer (Carlo Erba, Milan, Italy). A SP 2330 fused silica capillary column, 30 m x 0.32 mm I.D., 0.20 µm film thickness (Supelco, Inc., Bellefonte, PA) was employed. The chromatographic conditions were: column temperature programmed from 100°C (kept for 2 min) to 250°C at 10°C/min (maintained for 10 min), injector and detector temperature 270°C, carrier gas (helium) and flow rate 2.0 mL/min. Transfer line temperature was kept at 260°C. A mass spectrometer scanned from m/z 100 to m/z 400 with a 0.5 s cycle time. The ion source was set at 180°C and spectra were obtained by electron impact (70 eV). Identification of compounds was carried out by comparison of retention times and mass spectra of standards.
Sodium hydroxide was obtained from BDH (Poole, UK). Methanol, n-hexane, n-heptane, methylene chloride, chloroform, anhydrous sodium sulfate and sodium chloride were purchased from Merck (Darmstadt, Germany). Palmitic acid methyl ester (C16-ME, 99% purity), oleic acid methyl ester (C18:19-ME, 99% purity), and linoleic acid methyl ester (C18:26-ME, 99% purity) were purchased from Sigma-Aldrich (Milano, Italy).
Preparation of Amanita virosa extract:
Amanita virosa was collected in August 2011 in central western Slovenia. Within 24 h of collection, it was dried in an air-flow chamber at 30-35°C and then stored at -20°C. A mushroom specimen was deposited for evidence at the Department for Pharmaceutical Biology at the Faculty of Pharmacy, Ljubljana (No: FB-2011/002). The freshly frozen mushroom (100 g) was disrupted into small pieces and homogenized with 200 mL CH 2 Cl 2 . The homogenate was exposed to ultrasound for 10 min, macerated at room temperature for 12 h and again exposed to ultrasound for 10 min. The resulting homogenate was then centrifuged at 1100 g for 10 min.
Sub-fractionation of extract from Amanita virosa:
Dry extract (10 g) was dissolved in methanol, mixed with 3 g of silica gel and evaporated in vacuo. The dry extract was chromatographed on silica gel using CH 2 Cl 2 /MeOH (10:0.5, v:v), CH 2 Cl 2 /MeOH (10:1, v:v) and MeOH to give 7 fractions, denominated 1-7, respectively. Fraction 3, eluted with CH 2 Cl 2 /MeOH (10:0.5, v:v), was concentrated in vacuo and submitted to CC over silica gel using Nhexane/diethyl ether (1:1, v:v) as eluent to afford fractions 3A and 3B, respectively. Fraction 5, eluted with CH 2 Cl 2 /MeOH (10:1, v:v) was concentrated in vacuo and submitted to repeated CC over silica gel using CH 2 Cl 2 /MeOH (10:1.5, v:v) as eluent to afford fractions 5A and 5B, respectively. The fractions obtained by subfractionation of the extract were tested for inhibitory activity.
Determination of inhibitory activity:
Inhibitory activity of fungal fractions on human thrombin (Sigma, St. Louis, Missouri, USA) was determined in 96-well microtiter plates using chromogenic substrates H-D-phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide dihydrochloride (S-2238) (Chromogenix, Milano, Italy). The stock solutions of the enzyme and substrates were prepared according to the manufacturer's instructions. To determine thrombin inhibition, 40 µL HBSA buffer (pH 7.5) containing 10 mM Hepes (Sigma), 150 mM NaCl, and 0.1% bovine serum albumin (Sigma) was mixed with 50 µL thrombin solution (0.5 NIH units/mL) (all concentrations in parentheses are final concentrations in the mixture). Ten µL of fungal fraction dissolved in dimethyl sulfoxide (DMSO) (120 µg/mL) was added to bring the total volume of the mixture to 100 µL. After incubation at room temperature for 15 min, 50 µL substrate (0.5 mmol/L) was added. A mixture without enzyme (blank sample) and a mixture without the fungal fraction (negative control) were introduced by analogy for every fungal fraction. Thrombin inhibitor argatroban (Daiichi, Tokyo, Japan) at a concentration of 0.1 µg/mL was substituted for the fungal fraction to serve as a positive control. After addition of chromogenic substrate, absorbance was measured with a Multiscan MCC/340 spectrophotometer (Titertek, Huntsville, Alabama, USA) at 405 nm every 30 s for a total duration of 20 min.
Change in absorbance directly reflects cleavage of the chromogenic substrate with release of p-nitroaniline. Absorbances of samples were corrected by subtracting the absorbance of the blank samples. The increase of absorbance per time unit (the x-slope of the graph) in the linear part of the graph (absorbance vs. time) showed reaction rate was defined as enzyme activity (A). For negative control, the activity was set to 100% and defined as A 0 . For each fraction, the thrombin activity in the reaction mixture with fungal fraction (A) was subtracted from the thrombin activity of the positive control. The difference was then expressed as a percentage of the thrombin activity of the negative control (A 0 ) and divided by A 0 . The result was then expressed as a percentage of the thrombin activity of the positive control and defined as the inhibitory activity (Eq.1). Inhibitory activity was tested in triplicate for each fungal fraction and the results averaged. 
Inhibitory activity (%) = [(A o -A blank ) /
Methanolysis of 1-3:
Fifty mg of 1-3 was refluxed with 4 mL of a 0.5 N solution of NaOH in MeOH for 20 min. The reaction mixture was employed in the next step without further purification. A solution of 1-3, after alkaline treatment, was heated with 5 mL of a solution of BF 3 /MeOH and refluxed for 2 min. The reaction mixture was extracted with n-heptane (2 mL) by refluxing for 1 min and then quenched with a saturated NaCl solution; the n-heptane phase, dried over Na 2 SO 4 , was filtered and evaporated under reduced pressure to give a mixture of fatty acid methyl esters, which were analyzed directly by GC-MS. The fatty acid methyl esters were identified by comparison with standards and the ratios calculated from the total peak areas.
